Literature DB >> 2840019

In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.

A W Chow1, N Cheng.   

Abstract

The in vitro activities of daptomycin (LY146032), paldimycin (U-70,138F), vancomycin, and penicillin G against 344 clinical isolates of anaerobic gram-positive bacteria were determined by an agar dilution method in calcium-supplemented (50 micrograms/ml) Wilkins-Chalgren medium, using an inoculum of 10(5) CFU. Daptomycin demonstrated excellent activity against a broad range of anaerobic gram-positive cocci and bacilli, including Peptostreptococcus, Eubacterium, Bifidobacterium, Actinomyces, Propionibacterium, and Lactobacillus species and Clostridium difficile. Highly resistant strains (MIC, greater than or equal to 64 micrograms/ml) were encountered sporadically from different genera, but these accounted for only 3% of all isolates tested. Vancomycin showed similar activity but was less active against Lactobacillus species and Peptostreptococcus prevotii. Paldimycin was inactive against most genera of anaerobic gram-positive bacteria. Overall, penicillin G remained the most broadly active agent against these isolates.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2840019      PMCID： PMC172278          DOI： 10.1128/AAC.32.5.788

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Authors:  N E Allen; J N Hobbs; W E Alborn
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032.

Authors:  M Y Dong; T W Chang; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  In vitro susceptibility of gram-positive cocci to paldimycin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

9.  Deficient autolytic enzyme activity in antibiotic-tolerant lactobacilli.

Authors:  K S Kim; J O Morrison; A S Bayer
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

10.  In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancer.

Authors:  K V Rolston; B LeBlanc; D H Ho; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191
View more
  8 in total

1.  Diagnosis?

Authors:  M A Miller
Journal:  Can J Infect Dis       Date:  1995-09

2.  Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria.

Authors:  Ingo Klare; Carola Konstabel; Sibylle Müller-Bertling; Rolf Reissbrodt; Geert Huys; Marc Vancanneyt; Jean Swings; Herman Goossens; Wolfgang Witte
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

3.  Propionibacterium acnes as a cause of prosthetic valve aortic root abscess.

Authors:  Federico Hinestrosa; Svetolik Djurkovic; Paul P Bourbeau; Michael A Foltzer
Journal:  J Clin Microbiol       Date:  2006-10-25       Impact factor: 5.948

4.  In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Authors:  Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Helen T Fernandez; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.

Authors:  Brea D Duval; Anselmo Mathew; Sarah W Satola; William M Shafer
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

6.  Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).

Authors:  P Canepari; M Boaretti; M M Lleó; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  The potential of antimicrobial peptides as biocides.

Authors:  Garry Laverty; Sean P Gorman; Brendan F Gilmore
Journal:  Int J Mol Sci       Date:  2011-10-06       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.